SYN - Synthetic Biologics on go with early-stage study with SYN-004

Institutional Review Board has signed off Phase 1b/2a trial evaluating Synthetic Biologics' ([[SYN]] +2.0%) SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant ((HCT)) recipients. Enrollment is expected to commence in Q1 of 2021.The 36-subject study will evaluate the safety, tolerability and potential absorption into the systemic circulation (if any) of 150 mg oral SYN-004 in allogeneic HCT recipients who receive intravenous beta-lactam antibiotic to treat fever.SYN-004 is an oral enzyme tablet that is co-administered with the antibiotics. By degrading beta-lactams, it helps maintain the normal balance of the gut microbiome and prevents unwanted effects such as diarrhea and Clostridium difficile infection.

For further details see:

Synthetic Biologics on go with early-stage study with SYN-004